title: The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.
abstract: Promyelomonocytic leukemia (PML) is a prominent oncosuppressor whose inactivation is involved in the pathogenesis of hematological and epithelial cancers. Here, we report that PML aggregated in nuclear bodies in syncytia elicited by the envelope glycoprotein complex (Env) of human immunodeficiency virus-1 (HIV-1) in vitro. PML aggregation occurred after the fusion of nuclei (karyogamy) within syncytia but before the apoptotic program was activated. The aggregation of PML was detectable in syncytia present in the brain or lymph nodes from patients with HIV-1 infection, as well as in a fraction of blood leukocytes, correlating with viral status. Using a range of specific inhibitors of PML (the oncogenic PML/RARalpha fusion product or specific small interfering RNAs), we demonstrated that, in Env-elicited syncytia, PML was required for activating phosphorylation of ataxia telangiectasia mutated (ATM), which colocalized with PML in nuclear bodies, in a molecular complex that also involved topoisomerase IIbeta-binding protein 1. PML knockdown thus inhibited the ATM-dependent DNA damage response that culminates in the activation of p53, p53-dependent transcription of pro-apoptotic genes and cell death. Infection of CD4-expressing cells with HIV-1 also induced syncytial apoptosis, which could be suppressed by inhibiting PML. Altogether, these data indicate that PML activation is a critical early event that participates in the apoptotic demise of HIV-1-elicited syncytia.
authors.affiliation: INSERM U848, Institut Gustave Roussy, Université Paris Sud, Paris 11, 39 rue Camille-Desmoulins, F-94805 Villejuif, France.
authors.forename: J-L
authors.initials: JL
authors.lastname: Perfettini
authors.forename: R
authors.initials: R
authors.lastname: Nardacci
authors.forename: C
authors.initials: C
authors.lastname: Séror
authors.forename: M
authors.initials: M
authors.lastname: Bourouba
authors.forename: F
authors.initials: F
authors.lastname: Subra
authors.forename: L
authors.initials: L
authors.lastname: Gros
authors.forename: G
authors.initials: G
authors.lastname: Manic
authors.forename: A
authors.initials: A
authors.lastname: Amendola
authors.forename: P
authors.initials: P
authors.lastname: Masdehors
authors.forename: F
authors.initials: F
authors.lastname: Rosselli
authors.forename: D M
authors.initials: DM
authors.lastname: Ojcius
authors.forename: C
authors.initials: C
authors.lastname: Auclair
authors.forename: H
authors.initials: H
authors.lastname: de Thé
authors.forename: M-L
authors.initials: ML
authors.lastname: Gougeon
authors.forename: M
authors.initials: M
authors.lastname: Piacentini
authors.forename: G
authors.initials: G
authors.lastname: Kroemer
mesh_terms: D017209:Apoptosis; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D015726:Giant Cells / Q000821:virology; D015497:HIV-1; D006367:HeLa Cells; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D034741:RNA, Small Interfering; D015398:Signal Transduction; D014157:Transcription Factors / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D054299:env Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
chemical_list: D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D034741:RNA, Small Interfering; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D054299:env Gene Products, Human Immunodeficiency Virus; C070576:PML protein, human; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases